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ABSTRACT 
This work focuses on the biophysical interactions of isoniazid (INH) and rifampicin 
(RIF), two commonly drugs used in the front-line treatment of tuberculosis (TB), with 
3D membrane models. Liposomes made of dipalmitoylphosphatidylcholine (DPPC) 
were used to mimic the human membranes, at the physiologic pH. In this study, INH’s 
and RIF’s membrane partition were evaluated, their preferential location within the 
membrane, and their effect on the biophysical properties of the membrane, which are 
believed to be related with the antimycobacterial compounds mechanisms of action. 
The INH’s and RIF’s lipophilicity was quantified by the partition coefficient (Kp) 
using derivative spectrophotometry. To predict the drug’s location across the 
membrane, fluorescence quenching studies were performed using liposomes labeled 
with two different fluorescence probes. To evaluate the effect of INH and RIF on the 
membrane’s biophysical properties, dynamic light scattering (DLS) was performed. 
The RIF’s and INH’s partition results revealed that both drugs establish, 
respectively, electrostatic and hydrogen bonds with the phospholipids head groups. 
Fluorescence quenching measurements allowed concluding that INH might be located 
at the surface of the membrane or deeply buried in the bilayer, reaching the aqueous 
vacuole. RIF initially interact with the phospholipids head groups, and then adopts a 
deeper position in the hydrocarbon core of the bilayer. Moreover, the changes in the 
biophysical parameters are in agreement with the abovementioned. Therefore this 
study may contribute to the discovery of novel drugs for TB chemotherapy. 
 
Keywords: Biophysical interactions, Dynamic light scattering, Fluorescence 
quenching, Liposomes, Partition coefficient, Tuberculosis.  
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RESUMO 
Este trabalho focou-se nas interações biofísicas da isoniazida (INH) e da rifampicina 
(RIF), dois fármacos geralmente utilizados no tratamento de primeira linha da 
tuberculose (TB), com modelos membranares 3D. Foram usados lipossomas 
constituídos por dipalmitoilfosfatidilcolina para mimetizar as membranas humanas a 
pH fisiológico. Assim, com estes modelos membranares foram avaliados parâmetros 
como a partição da INH e da RIF na membrana, as suas localizações preferenciais 
dentro desta e os seus efeitos nas propriedades biofísicas da membrana, que se 
acredita estarem relacionadas com os mecanismos de ação dos compostos 
antimicobacterianos. 
A lipofilicidade da INH e da RIF foi quantificada através do coeficiente de partição 
(Kp) através da espectrofotometria derivativa. Para prever a localização dos fármacos 
ao longo da membrana foram executados estudos de desativação de fluorescência, 
usando lipossomas marcados com duas sondas fluorescentes diferentes. Para avaliar o 
efeito da INH e da RIF nas propriedades biofísicas da membrana, foi realizada a técnica 
de “dynamic light scattering” (DLS).  
Os resultados da partição da RIF e da INH revelaram que os dois fármacos 
estabelecem, respetivamente, ligações eletrostáticas e de hidrogénio com as cabeças 
dos fosfolípidos. As medições de desativação de fluorescência permitiram concluir que 
a INH se deverá localizar a nível da superfície membranar ou profundamente inserida 
na bicamada, alcançando o vacúolo aquoso. A RIF inicialmente interage com a cabeça 
dos fosfolípidos, e depois adota uma posição mais profunda a nível da bicamada 
lípidica e junto às caudas hidrofóbicas. As alterações nos parâmetros biofísicos estão 
também de acordo com os resultados obtidos. Assim, este trabalho pode contribuir 
para a descoberta de novos fármacos para o tratamento da TB. 
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CHAPTER 1  
 
INTRODUCTION 
Tuberculosis (TB) is an infectious disease and, among the communicable diseases, 
is the second leading cause of illness and death worldwide after HIV/AIDS (human 
immunodeficiency virus/acquired immunodeficiency syndrome). It is estimated that 
one-third of the world’s population is infected with the etiologic agent of TB. TB is 
caused by the pathogen Mycobacterium tuberculosis (MTb), which has a unique cell wall, 
mostly made up from mycolic acids. This tubercle bacillus has the ability to penetrate 
the host phagocytic cells and there survive, multiply and interfere with the 
phagosome maturation pathway [1-3].  
Isoniazid (INH) and rifampicin (RIF) are front line drugs used in the treatment of 
TB. INH is a prodrug, and its activity, as anti-TB drug, requires its activation. Once 
activated, INH has a number of target functions, including inhibition of mycolic acids 
synthesis causing disturbances on the replication of the bacterium [4-6]. Despite the 
above mentioned, the mechanism of activation of this prodrug remains poorly 
understood and its mechanism of action is not fully established. RIF acts via the 
inhibition of deoxyribonucleic (DNA)-dependent ribonucleic (RNA) polymerase, 
leading to a suppression of RNA synthesis, protein synthesis and consequently cell 
death [7]. 
To achieve the purpose of this work, liposomes were used as membrane models of 
the human membranes. Liposomes are widely chosen in many studies to understand 
drug-membrane interactions. They possess an ordered molecular arrangement and 
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they can account the electrostatic forces, which make them excellent models to 
predict the interaction of drugs with the biological membranes [8,9].  
Dipalmitoylphosphatidylcholine (DPPC) was chosen, in this work, to formulate the 
liposomes, since it makes up to about one-third of total phospholipids present in the 
biologic membranes [10]. All the experiments were performed at the physiologic pH 
(i.e., pH = 7.4). 
 
The aim of this project is to study the interactions of INH and RIF, two anti-TB 
drugs, with 3D membrane models namely liposomes, with the purpose to analyse the 
membrane partition of the drugs, understand how they penetrate into the membrane, 
what are the membrane biophysical consequences of the drugs, and their preferential 
location within the lipid bilayer. These properties can be related to their mechanism 
of action, namely, their entrance into the cellular compartments and toxic effects and 
be helpful to identify novel biophysical mechanisms capable to explain the 
therapeutic effects of these antimycobacterial compounds, hence allowing the future 
development of more effective drugs. 
The work will then be divided in three major parts. The first will consist in the 
determination of the liposome/water partition coefficient, (Kp) to measure the drug’s 
lipophilicity using derivative spectrophotometry. Comparing with the octanol/water, 
this method allows a better description of the drugs distribution between aqueous 
and membrane phases, and a more reliable characterization of the drug interactions 
with the biological membranes. Derivative spectrophotometry will be used to 
determine Kp, in order to eliminate the light scattering caused by the lipid vesicles 
[9,11,12].  Dynamic light scattering (DLS) will be used to understand the influence of 
the drugs on the biophysical parameters of the membrane, such as cooperativity and 
the main phase transition temperature (Tm). The last part will be dedicated to the 
determination of the drugs location within the lipid bilayer by fluorescence 
quenching studies. Two probes, with constant fluorescence, will be used with a well-
known and different location within the lipid bilayer. The quenching constant, called 
Stern-Volmer constant (Ksv) is an indirect measure of the drug’s preferential location 
in the membranes. Therefore, a higher Ksv obtained indicates a greater proximity of 
the quencher (i.e. drug) to the probe [13].  
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CHAPTER 2  
CONTEXT 
2.1 Tuberculosis  
The history of tuberculosis (TB) mixtures with the history of humanity since TB is 
one of the oldest infectious diseases affecting mankind.  
In the past two decades, TB has gone from being a forgotten disease to a modern 
and recrudescent pathology, triggered by emergence of acquired immunodeficiency 
syndrome (AIDS) and an increase in homelessness and poverty in the developed 
world. The identification of multi-drug resistance (MDR) strains and extensively drug 
resistance (XDR) strains has worsened this public health concern. 
New effective drugs, better vaccines, and new diagnostic methods are desperately 
needed to change and overcome this situation.  
2.1.1 Epidemiology 
Currently TB ranks as the second leading cause of death from infectious disease 
worldwide, after the human immunodeficiency virus (HIV). According to the World 
Health Organization (WHO), in 2011, 8.7 million new cases of TB were estimated, 
which is equivalent to 125 cases per 100 000 population. Most cases where found in 
Asia (59%) and Africa (26%), with smaller proportions in the Eastern Mediterranean 
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Region (7.7%), the European Region (4.3%) and the Region of the Americas (3%) 
(FIGURE 1). 
The five countries that rank first to fifth in the world in terms of total numbers of 
incident cases in 2011 were India, China, South Africa, Indonesia and Pakistan. Of 8.7 
million incident cases, an estimated 0.5 million were children and 2.9 million occurred 
among women. About 13% of the worldwide TB caseload was HIV-associated and most 
of these cases were in the African Region [14]. 
 
FIGURE 1 TB incidence and prevalence rates in 2011. Estimated TB incidence rates (A). 
Estimated HIV prevalence in new TB cases (B). Reproduced from Global Tuberculosis Report [14]. 
 
A 
B 
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In 2011, TB killed approximately 1.4 million people worldwide, of whom 430 000 
were HIV-positive and the other 990 000 HIV-negative. These deaths included 0.5 
million among women, making TB one of the top killers of women worldwide. 
In FIGURE 2 is possible to observe that, globally, incidence rates are declining. 
Therefore, from 1990 up to around 2011 the incidence rates were relatively slow, and 
then started to fall. If this trend is sustained global targets for TB control set for 2015 
will be achieved: incidence should be falling and the prevalence and death rates 
should be halved compared to 1990.  
In addition, people who are latently infected constitute the hidden reservoir of 
the disease from which new cases of active TB can emerge.  
 
FIGURE 2 Global trends of TB incidence, prevalence and mortality. Left: Global trends in 
estimated rates of TB incidence including HIV-positive TB (green) and estimated incidence rate of HIV-
positive TB (red). The horizontal dashed lines represent the targets of a 50% reduction in prevalence 
and mortality rates by 2015 compared with 1990. Shaded areas represent uncertainty bands. Mortality 
excludes TB deaths among HIV-positive people (A). Estimated absolute numbers of TB cases and deaths 
(in millions) (B). Reproduced from Global Tuberculosis Report [14]. 
 
 
A 
B 
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2.1.2 Pathophysiology 
TB is an airborne disease initiated by the inhalation of droplets (aerosols) 
containing a small number of the bacilli Mycobacterium tuberculosis (MTb) [15]. The 
bacilli diffuse from the site of initial infection, in the lung, through the lymphatic and 
blood to other parts of the body. The contamination is spread through the air when 
sick people with pulmonary TB expel bacteria, for example by coughing [16]. 
Once in the lung, one of the first interactions between MTb and the host is with 
the innate immune system, more specifically the resident macrophages (i.e., alveolar 
macrophages) responsible for the phagocytosis mediated by various host receptors. 
Most immunocompetent individuals either eliminate MTb or contain it in a latent 
state. According to appropriate stimuli, alveolar macrophages activate, and response 
effectively by transferring the phagocytized MTb to the destructive environment of 
lysosomes. Although some bacilli are able to escape lysosomes digestion, survive and 
multiply within the macrophage creating a dynamic balance between bacterial 
persistence and host defense develops [16-18]. This balance might be lifelong, since 
only a minority (approximately 10%) develops active clinical disease. In fact in most 
healthy individuals, the immune defense system retains sufficient control over 
replication of the bacterium such that the individual remains free of tissue damage 
and symptoms, in a so-called state of latency [19]. 
2.1.2.1 Tuberculosis types 
Although TB can affect any organ, the pulmonary TB is the most common 
manifestation of the disease, being the lung the main organ affected by the disease. 
Extrapulmonary TB has been used to describe the infection at body sites other than 
the lung, as for example, in the liver, kidney, spine, brain, etc. In addition, 
extrapulmonary TB may coexist with pulmonary TB as well. Symptoms and signs can 
be specific of the disease or non-specific, such as fever, weight loss, and night sweats. 
TABLE 1 represents the pathogenesis of different TB cases and their distribution [20-
22]. 
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TABLE 1 Pathogenesis and distribution of different TB cases. Distribution of TB cases in HIV- 
negative patients (brown) and in HIV-positive patients (black). PTB, pulmonary tuberculosis; LNTB, 
lymph node tuberculosis; GUTB, genitourinary tuberculosis; MTB, military tuberculosis; TBM, 
tuberculosis meningitis; ABD, abdominal tuberculosis. Data collected from[20-22]. 
Case Pathogenesis Distribution 
PTB Lung’s infection. 
75% 
30% 
Both 
5%  
50%  EPTB 
LNTB 
Local manifestation of a systemic disease. MTb undergoes 
haematogenous and lymphatic dissemination. Cervical adenopathy is the 
most common. 
35% 
15% 
20% 
Pleural TB Rupture of a diseased area into the pleural space. 20% 
Bone and Joints TB Commonly affects the thoracic spine and hip joint. 10% 
GUTB 
Renal disease may be the result of direct infection of the kidney and 
lower urinary tract or may present as secondary amyloidosis. 9% 
MTB Any progressive, disseminated form of TB. 8% 
TBM Neurological TB with intense inflammation following rupture of a subependymal tubercle into the subarachnoid space. 5% 
ABD 
Encompass TB of the gastrointestinal tract, peritoneum, omentum, 
mesentery and its nodes and other solid intra-abdominal organs such as 
liver, spleen and pancreas. 
3% 
Others 
For example: tuberculous pericarditis, and TB associated with tumor 
necrosis factor-α (TNF-α) inhibitors. 10% 
2.1.2.2 Microbiology of Mycobacterium tuberculosis 
The German physician, Robert Koch, first discovered MTb in 1882. This pathogenic 
bacillus is an obligate aerobe rod-shaped, acid-fast, non-encapsulated, non-spore 
forming and non-motile. It grows most successfully in organs with a high oxygen 
content, such as the lungs [23,24]. The unusual and robust MTb cell envelope is lipid-
rich, composed of mycolic acids, and conferring capacity to the bacteria to survive in 
the host environment and resist to drug therapy. The cell wall composition is also 
responsible for the impermeability to basic bacteriological dyes, thus MTb is neither 
Gram-positive nor Gram-negative, but instead is classified as acid-fast using Ziehl-
Neelsen method. The process of cell division of MTb is extremely slow, 15-20h, when 
compared with other bacteria, plus the ability to persist in latent state results in the 
need of long treatment duration of several anti-TB drugs [17,24,25]. 
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2.1.2.3 Host-pathogen interactions 
One of the first interactions between MTb and the immune system is with the 
macrophages and seems to be mediated by pattern recognition receptors. Cholesterol 
has been shown to act as a docking site for the pathogen promoting receptor-ligand 
interactions [18]. The precise receptor involved in the initial interaction influences 
the subsequent fate of MTb and the survival changes of the mycobacteria within the 
macrophage [17]. To persist in the host, MTb arrests the phagosome at an early stage 
of maturation, thereby preventing phago-lysosomal fusion and acidification of 
infected phagosomes. In addition, MTb also partially inhibits the activation of 
infected macrophages by interferon (IFN)-ϒ, residing in an environment that is only 
slightly acidic, with a pH of ~6.2 [1,26].  
As a result, some mycobacteria persist in the lung, in a latent state, within 
structures termed granulomas. The granulomas (FIGURE 3) are structured clusters 
containing different types of immune cells (particularly T lymphocytes and 
macrophages), endothelial cells and dendritic cells, among others. This structure 
likely represents a balance between a potentially dangerous pathogen and the host 
immune system, since provides housing for MTb during a long period of time, but also 
prevents the spreading of the bacilli [15,17,27]. Nevertheless, the inactivation of 
macrophages and the arrest of phagosomal maturation are not all-or-nothing events. 
Some macrophages can become activated and mycobacteria phagosomes can proceed 
in developing to more mature stages of the phagolysosomes, acidifying to a pH of 4.5 
to 5.0. It is believed that at least some proportion of the bacteria is effectively 
resistant to the level of acid in the phagolysosome [1]. 
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FIGURE 3 Stages of granuloma formation in TB. Initially occurs the expansion of the bacterial 
population in the absence of adaptive immunity. Later initiation of adaptive immunity occurs, CD4+ and 
CD8+ effector T lymphocytes are recruited to infected tissue and curtail bacterial growth. Finally, the 
mature granuloma represents the equilibrium between virulent mycobacteria and the host immune 
response. Data collected from [16]. 
2.1.3 Tuberculosis Treatment 
In the past two decades, there has been the worldwide emergence of MDR, XDR 
and more recently strains that are resistant to all anti-TB drugs. MDR is defined as 
mycobacteria resistance to, at least, two anti-TB drugs, rifampicin (RIF) and isoniazid 
(INH), whereas XDR is defined to MDR with additional resistance to, at least, one 
injectable second-line anti-TB drug plus a fluoroquinolone [28]. Globally 3.7% of new 
cases and 20% of previously treated cases of TB were estimated to have MDR [14]. 
The goals of treatment include cure without subsequent relapse, prevention of 
death, impediment of the transmission, and prevention of the emergence of drug 
resistance. Currently, TB chemotherapy consists of, at least, 6-month therapy using 
first-line drugs [16]. Treatment of TB and drug resistance cases requires multi-drug 
therapy, comprising: 
 
Evaluation of isoniazid and rifampicin on the biophysical properties of the membrane studied with 3D model 
 
 10 
1) Initially, an intensive phase of RIF, INH, pyrazinamide (PZA) and 
ethambutol (ETB) daily for 2 months. 
2) A continuation phase of RIF and INH for a further 4 months, either daily or 
three times per week. 
If the treatment fails as a result of MDR, or intolerance to one or more drugs, second-
line anti-TB drugs are used, such as para-aminosalicylate, kanamycin, rifabutin, 
fluoroquinolones, capreomycin, ethionamide and cycloserine, that are in general 
more toxic with serious side effects [29]. These current TB treatment protocols, 
despite highly effective, are lengthy, usually 6-9 months, which contributes to the 
non-patient compliance to the therapy being the cure rate unsatisfactory (FIGURE 4) 
[16]. 
 
FIGURE 4 Clinical problems of current TB chemotherapy treatment. Data collected from [30]. 
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2.2 Isoniazid  
For more then a half a century, INH has been an essential front line drug used in 
TB chemotherapy, since its discovery in 1952 [31]. INH is a prodrug and requires 
activation before it becomes therapeutically active. Its mechanism of action seems to 
be related with the inhibition of the mycolic acids [4].  
Chemically, INH (FIGURE 5) is a hydrazide of isonicotinic acid with three pKa 
values: 1.8 for the basic pyridine nitrogen; 3.5 for the hydrazide nitrogen; 10.8 for the 
hydrazide group [32]. At the physiologic pH (pH = 7.4), INH is a neutral specie, since 
only a tiny percentage is in the ionized form  (0,01%, predicted using MarvinView® 
5.4.1.1 software from ChemAxon), so the interactions between the drug and the 
liposomes are expected to be mainly due to the hydrophobic and hydrogen bonds [8]. 
Following oral administration, INH is readily absorbed and does not bind to 
plasma proteins (plasma half-life: 1 - 1.15 h) being well distributed to different body 
tissues and fluids. Because of this widespread distribution, INH is an anti-TB drug 
effective against all types of TB [33]. 
 
FIGURE 5 Chemical structure of INH. 
 
This front line drug undergoes significant first pass hepatic metabolism, meaning 
that, is mainly metabolized by the liver via acetylation by the enzyme N-
acetyltransferase to the inactive acetyl-INH. Since the rate of acetylation it is 
genetically dependent, patients can be categorized as fast acetylators (half-life: 0.5 - 
1.6 h) and slow acetylators (half-life: 2 - 5 h). In slow acetylators, INH is slowly 
metabolized resulting into more prolonged plasma levels of the drug and possibly 
more adverse effects than in rapid acetylators. Acetyl-INH can be further hydrolyzed 
and acetylated forming the mono-acetylhydrazine that can be converted into 
hydrazine, which is though to be associated to hepatotoxicity of INH, a major adverse 
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effect [34,35].  Other side effects include dryness of mouth, epigastric distress, allergic 
reactions, peripheral neuritis, mental abnormalities and methaemoglobinemia. 
2.2.1 Mechanism of Action of Isoniazid  
INH is one of the most effective bactericidal synthetic therapeutic drug for the 
treatment of TB. INH enters the mycobacteria cell through passive diffusion [36]. The 
anti-TB function of INH requires its in vivo activation by the MTb catalase-peroxidase 
enzyme KatG. The katG gene encodes the former protein and mutations contribute to 
the loss of its function, and consequently MTb resistance to INH [31,37]. Once 
converted in the activated inhibitor form, INH has a number of proposed targets in 
the mycobacteria cell, such as the enoyl-acyl carrier protein reductase (InhA) and the β-ketoacyl acyl carrier protein synthase, leading to mycolic acid biosynthesis 
inhibition, long-chain fatty acid accumulation, and bacteria death [38]. 
The mechanism of action of INH still remains poorly understand and drug-
membrane interaction studies may help to unveiling the mechanism of action of this 
drug. 
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2.3 Rifampicin  
RIF is one of the most potent and broad bactericidal antibiotics and is a key drug 
of the anti-TB therapy. This semisynthetic drug belongs to rifamycin group and is a 
fermentation product of Streptomyces mediterranei. RIF was introduced in the market 
in 1968 and has greatly shortened the duration of TB chemotherapy [7,39]. The 
mechanism of actin of RIF is related with the inhibition of the bacterial RNA synthesis 
[16]. 
Chemically, RIF (FIGURE 6) is predominantly a zwitterion, being 40% of the 
molecules negatively charged at the physiologic pH, with two pKa values: 1.7 related 
to 4-hydroxy and 7.9 related to 3-piperazine nitrogen [8]. 
 
FIGURE 6 Chemical structure of RIF. 
 
This anti-TB drug can be administered via oral or parental route (intravenous 
injection) and has higher bioavailability. Once ingested RIF is readily absorbed from 
the gastrointestinal tract and a large amount of drug binds to plasma proteins (half-
life: 1.5 - 5 h) [39]. This front-line drug is widely distributed trough the body, diffusing 
freely into tissues, living cells and bacteria, making it extremely effective against 
intracellular pathogens like MTb [7]. 
The liver enzymes metabolize approximately 85% of RIF. RIF undergoes 
enterohepatic recirculation and is rapidly deacetylated to its main and active 
metabolite – desaetylrifampicin. The most serious adverse effect is related to RIF 
hepatotoxicity. The more common side effects include fever, gastrointestinal 
disturbances, rashes, discoloration of the skin and body fluids and immunological 
reactions [39]. 
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2.3.1 Mechanism of Action of Rifampicin  
RIF is thought to specific inhibits bacterial deoxyribonucleic acid (DNA)-
dependent ribonucleic acid (RNA) chain synthesis by inhibiting bacterial DNA-
dependent RNA polymerase [7,40]. This drug binds to the RNA polymerase active 
subunit and blocks RNA synthesis by physically preventing elongation of RNA 
products beyond a length of 2-3 nucleotides. However, it does not affect mammalian 
RNA polymerase and hence not interfere with the RNA synthesis [7,41]. Several 
studies provide evidence that resistance to RIF arises from mutations in rpoB gene, 
which encodes the β  subunit of RNA polymerase [42].  
RIF is a key component of anti-TB chemotherapy, however bacteria, such as MTb, 
develop resistance to this drug with high frequency restricting the utility of its use for 
treatment of TB or emergencies. A more detailed knowledge about the mechanism of 
action of RIF may be obtained by the biophysical studies of the drug-membrane 
interactions.
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2.4 Biological Membranes 
Biological membranes present a highly complex, dynamic and fluid architecture, 
with only a few nanometers thick, mainly composed of a lipid bilayer of water-
insoluble amphiphilic compounds, particularly the phospholipids, with embedded 
proteins. The phospholipids are amphipathic lipids and present a hydrophilic head 
group facing outwards (medium) and hydrophobic tails directed towards each other 
[43,44]. Basic proteins, cholesterol, glycolipids and other molecules are usually 
inserted in biological membranes in such a way that confer the bilayer the functional 
properties appropriate for the particular membrane. 
There are four main classes of phospholipids: phosphatidylcoline, 
phosphatidylethanolamine, phosphatidylserine and sphingomyelin [45]. One of the 
main components of eukaryotic membranes are the phosphatidylcholines (PC). PC are 
also critical constituents of human lung surfactant, serum lipoproteins, and bile and 
represent the most widely used lipid in model membrane studies [46]. 
Lipid bilayers present many lamellar phases as a function of temperature, namely 
gel phase (Lβ), liquid-crystalline phase (Lα), subgel phase (Lc), and ripple phase (Pβ). 
Above a characteristic temperature of each lipid, the main phase transition 
temperature (Tm), the bilayer is in a Lα phase, in which the lipid acyl chains are fluid 
and disordered, below that temperature the phospholipids are in an ordered Lβ phase. 
It is widely accepted that many biologically relevant processes occur in the Lα phase, 
were the hydrocarbon chains are in a disordered state [47,48]. 
2.4.1 Membrane Models 
In the past years, a considerable number of simple model membranes have been 
constructed in attempts to face the complexity of their biological counterparts and 
capture, at a molecular level, some of the essential features of drug-membrane 
interactions. There are many different types of membrane models, such as: 
♦ Micelles: are constituted by surfactant molecules, that self-assemble in 
aqueous solutions at concentrations above the critical micelle concentration. 
This aggregate presents the hydrophilic head group in contact with the 
surrounding solvent, sequestering the hydrophobic single tail in the center 
[49]; 
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♦ Langmuir monolayers:  are a monomolecular film formed at the air-water 
interface [50]; 
♦ Liposomes: are self-closed vesicles composed of one or more lipid bilayers 
that encapsulate water [51]; 
♦ Supported Lipid Bilayers (SLBs): consists on a lipid bilayer deposited on a 
solid support, being the upper face the only one exposed to the solvent, 
providing great stability [52]. 
Among a variety of simplified membrane models, liposomes represent simple and 
reliable membrane models and therefore were used in the work to assess drug-
membrane interactions [30]. 
2.4.2 Liposomes 
Liposomes (also known as lipid vesicles) are closed spherical vesicles composed of 
one or more lipid bilayers. These structures are composed of amphiphilic molecules, 
with a hydrophilic head group and hydrophobic lipid tails, which are generally a 
synthetic derivative of a natural phospholipid, often dipalmitoylphosphatidylcholine 
(DPPC). The phospholipids spontaneously self-assemble into one or more concentric 
bilayers when placed in an aqueous medium, with the polar head groups in contact 
with the aqueous phase, and the fatty acids orientated towards each other forming 
the hydrophobic core shielded from the water [51,53]. Liposomes size (diameters) 
varies between 20 nm to several dozens micrometers, whereas the thickness of the 
phospholipid bilayer membrane is approximately 4-7 nm [54].  
2.4.2.1 Liposomes Classification 
Liposomes are commonly classified according to their size and number of lamellae 
(FIGURE 7). With respect to the number of bilayers it is possible to distinguish 
between [30]: 
♦ Multilamellar vesicles (MLVs): they are a result of the thin film hydration 
method and are liposomes with multiple concentric bilayers within a single 
particle. Their size range from a few hundred to thousands of nanometers; 
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♦ Unilamellar vesicles (ULVs): when MLVs are sonicated or extruded, through 
a filter, occurs the formation of ULVs, which consist of a single membrane 
bilayer. Regarding their size, ULVs can be further classified into: 
• Small Unilamellar vesicles (SUVs): with a diameter below 100 nm; 
• Large Unilamellar vesicles (LUVs): with a diameter above 100 nm. 
 
FIGURE 7 Liposomes classification regarding their size and number of lipid bilayers. MLVs: 
Multilamellar vesicles; ULVs: Unilamellar vesicles; SUVs: Small lamellar vesicles; LUVs: Large lamellar 
vesicles. Data collected form [30]. 
2.4.2.2 Liposomes Preparation 
MLVs are commonly prepared by lipid hydration method. In this method, 
liposomes are prepared by evaporation to dryness of a lipid solution, so that a thin 
phospholipid film is formed. Hereafter, the film is hydrated above the Tm of the lipid, 
by adding aqueous buffer and vortexing the dispersion. The suspension of MLVs 
produced is then extruded under nitrogen through polycarbonate filters (100 nm) to 
form LUVs [55]. These latter liposomes were used as the membrane models in all the 
experimental assays in this work. All these processes are illustrated in FIGURE 8. 
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FIGURE 8 MLVs and LUVs preparation. (1) Addition of the aqueous buffer to the phospholipid 
film; (2) Vortexing releases the lipid film from the flask walls; (3) The phospholipids aggregate into 
large liposomes with multiple bilayers – MLVs; (4) A population with a relatively narrow homogeneous 
size distribution constituted by one single bilayer – LUVS can be prepared by extrusion of liposomes 
through polycarbonate filters with well defined porous [30]. 
2.4.2.3 Dipalmitoylphosphatidylcholine 
Dipalmitoylphosphatidylcholine (DPPC) was chosen in this work, since it is a 
representative phospholipid of the biological cell membranes. DPPC is composed of a 
polar head, phosphatidycholine, which in turn is composed of a phosphate group 
(negatively charged) and a choline (positively charged). It also has in its constitution 
two fatty acids chains, dipalmitoyl, with 16 carbon atoms each (FIGURE 9). This fully 
saturated phospholipid has a transition temperature around 41 ºC and at body 
temperature is in the gel phase [56].  
DPPC makes up to about one-third of total phospholipids presents in the body, 
also accounts for 10-20% of the PC content of brain myelin and erythrocyte 
membranes, being one of the major components of the pulmonary surfactant [10]. In 
pulmonary TB, the first physiological barrier encountered by the inhaled MTb is the 
pulmonary surfactant. The lung surfactant is a complex mixture of lipid and proteins 
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complex that lines the pulmonary alveoli as a surfactant monolayer at the air-
aqueous interface [57,58]. 
According to the above-mentioned DPPC liposomes represent a suitable model to 
study INH and RIF interactions with the biological membranes and get a higher 
knowledge about its mechanism of action. 
 
 
FIGURE 9 Chemical structure of DPPC. 
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CHAPTER 3  
MATERIALS AND METHODS 
3.1 Reagents 
INH and RIF were obtained from Sigma–Aldrich Co. (St. Louis, MO, USA). DPPC was 
purchased from Avanti Polar Lipids (Alabaster, AL, USA). The probes 1,6-diphenyl-
1,3,5-hexatriene (DPH) and 1-(4-trimethylammonium)-6-phenyl-1,3,5-hexatriene 
were obtained from Molecular Probes (Invitrogen, Paisley, UK). All other chemicals 
were purchased from Merck. 
Drug solutions were prepared with phosphate buffer at pH 7.4. This buffer was 
prepared with double-deionized water (conductivity less than 0.1 µS cm-1) from a 
Millipore system, and the ionic strength (I = 0.1 M) was adjusted with NaCl. 
3.2 Preparation of liposomes 
Liposomes were prepared according to the thin film hydration method. Concisely, 
the lipid, DPPC, was dissolved in a chloroform/methanol mixture. The organic 
solvents were then evaporated under a stream of nitrogen using a rotary evaporator 
to yield a dried lipid film. The resultant lipid film was hydrated with a buffer 
(phosphate: 0.1 M, I = 0.1 M, pH 7.4) and the mixture was vortexed to yield MLVs. Lipid 
suspensions were then equilibrated at 60 ºC (temperature above the main phase 
transition temperature) for 30 min and were further extruded one time through 
polycarbonate filters with a pore diameter of 600 nm, followed by one time with the 
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filters with a pore diameter of 200 nm and finally were extruded ten times through 
filters with a pore diameter of 100 nm, at 60 ºC, to form LUVs. 
For DPH and TMA-DPH labeled liposomes, the probe was co-dried and with the 
lipid and incorporated in a ratio of 1:300 (probe:lipid). 
3.3 Determination of INH’s and RIF’s partition coefficients by 
derivative spectrophotometry 
The partition coefficient (Kp) of INH and RIF between LUVs suspensions of DPPC 
and buffer solution, at the physiologic pH, was determined by derivative 
spectrophotometry. Phosphate buffer solution was added to liposomes containing a 
fixed concentration of INH (150 µM) or RIF (30 µM) and increasing concentrations of 
DPPC (50, 100, 200, 300, 400, 500, 600, 700, 900, 1000 µM). The correspondent reference 
solutions were identically prepared in the absence of drug. All suspensions were then 
vortexed and incubated above the main phase transition temperature of the lipid (i.e. 
60 ºC). The absorption spectra were recorded at 60 ºC by a Perkin-Elmer Lambda 45 
UV-Vis spectrophotometer, using quartz cells with a 1 cm-1 path length and a spectral 
range from 250 to 550 nm at 1 nm intervals. The mathematical treatment of the 
results was performed using a developed routine, Kp calculator. 
3.4 Membrane location studies by fluorescence quenching 
The INH’s and RIF’s membrane location studies were assessed by steady-state 
fluorescence quenching measurements, using two fluorescence probes (DPH and 
TMA-DPH) in liposomes’ buffered suspensions prepared with DPPC at pH 7.4, with a 
well-established and documented membrane position and depth [59,60]. The studies 
were carried out by incubation of drugs with the labeled liposomes. It was used a 
fixed concentration of DPPC (500 µM) and increasing concentrations of INH (0-150 
µM) and RIF (0-100 µM). The resultant suspensions were incubated, protected from 
the light, for 30 min at a temperature above the main phase transition temperature of 
DPPC (60 ºC), allowing INH and RIF to reach the partition equilibrium between the 
lipid membranes and the aqueous medium. Measurements were carried out at a 
controlled temperature (60 ºC).  
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Fluorimetric data were obtained using a Jasco FP-6500 spectrofluorometer (Jasco, 
Great Dunmow, UK) equipped with a constant temperature cell holder. The excitation 
wavelength was set to 357 nm for DPH and 360 nm for TMA-DPH. The emission 
wavelength were set to 427 nm for DPH and 430 nm for TMA-DPH [59-61]. 
 All fluorescence intensity data were corrected for the quencher absorbance at the 
excitation wavelength. 
3.5 Membrane biophysical properties studies 
To evaluate the effect of INH (30 µM) and RIF (30 µM) on the biophysical 
parameters (Tm and cooperativity) of DPPC liposomes (500 µM), a DLS technique was 
performed, as previously described [62].  
The count rate was collected using a BI-MAS DLS instrument (Brookhaven 
Instruments, USA), containing a controlled temperature cell holder. The samples 
were heated from 30 ºC to 60 ºC with intervals of 1 ºC with an equilibration period of 2 
min. At each temperature, 6 runs of 2 min were performed. 
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CHAPTER 4  
RESULTS AND DISCUSSION 
4.1 Drug’s membrane partition 
The drug’s pharmacokinetics is greatly influenced by the lipophilicity. Drug’s 
absorption, metabolism, binding and distribution are affected by this physicochemical 
factor. In general, the higher the lipophilicity of a drug, the higher its permeability, 
thus its absorption, the stronger its binding to protein and the greater its distribution 
through the body [63]. In addiction, an increment in the lipophilicity of an 
antimycobaterial agent positively affects the entry into the hydrophobic 
mycobacterial membranes and its efficacy [60]. 
The main predictive index of lipophilicity is a computational value, logarithm of 
the partition coefficient (LogP), which represents the octanol solubility of a given 
compound in the presence of aqueous solute. Generally, desirable antimycobacterial 
candidates should have a value for LogP between 1.3 and 4.1 [64]. Since INH and RIF 
are ionizable compounds, the partition becomes pH dependent an then, the 
lipophilicity is normally represented by the distribution coefficient (LogD). 
The Kp of INH and RIF, expressed in term of LogD, has been determined in a 
liposome/buffer system using derivative transformation UV spectroscopy, since this 
model constitutes a more realistic prediction of drug behaviour in biological 
environments, in comparison with the unsatisfactory octanol/water partition 
method. Is also able to characterize the extent of drug penetration into the 
membrane and/or interactions with phospholipids or other membrane components, 
 
Evaluation of isoniazid and rifampicin on the biophysical properties of the membrane studied with 3D model 
 
 24 
mimicking better the hydrophobic part and the outer polar and negatively charged 
surface of the lipid bilayers [12,60,61]. Furthermore, derivative spectroscopic 
techniques combined with liposome/buffer system allow determining the drug 
distribution between the lipid and buffer media, without the need to quantify the 
drug separately in each media. Moreover, the intense background signals of lipid 
vesicles light scattering can be eliminated by the use of derivative spectrophotometry 
that additionally provides a better resolution of overlapped bands [59,65].  
After equilibration, the absorption spectra were recorded. The partition 
coefficients were calculated from the second and third derivative spectra (determined 
from the recorded absorption spectra after blank subtraction) at the wavelength 
where the scattering is eliminated, by fitting Eq. (1) to the experimental data (DT 
versus [L]) using a nonlinear least- squares regression method where the adjustable 
parameter is the partition constant, Kp [60,61,65]: 
 𝐷! = 𝐷! + 𝐷! − 𝐷! 𝐾![𝐿]𝑉!1 + 𝐾![𝐿]𝑉!  
 
(1) 
In this equation, D is the second or third derivative intensity (D = (dnAbs)/(dλn)) 
obtained from the absorbance values of the total amount of INH or RIF (DT); INH or RIF 
distributed on the lipid membrane phase (Dm); INH or RIF distributed in the aqueous 
phase (Dw); lipid concentration ([L]); and the lipid molar volume (Vm). For DPPC, the 
mean molecular weight is 734.05 gmol-1 and Vm is 0.70 Lmol-1 [61]. 
In FIGURE 10 is showed, as an example, the absorption (A), the second (B) and the 
third (C) derivative spectra of INH with different concentrations of LUVs of DPPC at 
pH 7.4 and 60 ºC. The wavelength of the maximum absorption of INH (FIGURE 10C) 
exhibits a slight decrease in the intensity with increasing DPPC concentration, 
providing an indication that the partition of the drug to the lipid bilayers happens 
[9,65]. The Kp values were obtained by fitting Eq. (1) to experimental third derivative 
spectra data (Dt vs. [L]) for 150 µM drug concentration, using a non-linear least-
squares regression method at wavelength where the scattering is eliminated [61,66]. 
FIGURE 10D shows the best fit of the Eq. (1) to the third derivative 
spectrophotometric data collected at λ  = 304 nm for INH with different concentrations 
of DPPC liposomes. 
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FIGURE 10 Absorption spectra (A), second (B) and third (C) derivative spectra of INH (150 
µM) incubated in DPPC liposomes (orange lines) and DPPC without drug (black lines) with 
different concentrations (M): (1) 0, (2) 5 × 10-5, (3) 1 × 10-4, (4) 2 × 10-4, (5) 3 × 10-4, (6) 4 × 10-4, 
(7) 5 × 10-4, (8) 6 × 10-4, (9) 7 × 10-4, (10) 9 × 10-4, (10) 1 × 10-3. The curve (D) represents the best 
fit by Eq. (1) using a nonlinear least-squares regression method at wavelength 304 nm where the 
scattering is eliminated. 
 
FIGURE 11 presents, as an example the absorption and the second derivative 
spectra of RIF with different concentrations of LUVs of DPPC at pH 7.4 and 60 ºC. The 
derivative spectra of RIF in DPPC liposomes, exhibits an increase in the intensity of 
the wavelength of the maximum absorption (FIGURE 11B), an observation that 
provides a clear indication that the drug partition happens, from the aqueous to the 
lipid bilayer [9,65]. The Kp values were obtained by fitting Eq. (1) to experimental 
second and third derivative spectra data (Dt vs. [L]) for 30 µM drug concentration, 
using a non-linear least-squares regression method at wavelength where the 
scattering is eliminated [61,66]. FIGURE 11C shows, as an example, the best fit of the 
Eq. (1) to the second-derivative spectrophotometric data collected at λ = 363 nm for 
RIF with different concentrations of DPPC liposomes.  
1 
11 
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C 
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FIGURE 11 Absorption spectra (A) and second (B) derivative spectra of RIF (30 µM) incubated 
in DPPC liposomes (orange lines) and DPPC without drug (black lines) with different 
concentrations (M): (1) 0, (2) 5 × 10-5, (3) 1 × 10-4, (4) 2 × 10-4, (5) 3 × 10-4, (6) 4 × 10-4, (7) 5 × 10-4, 
(8) 6 × 10-4, (9) 7 × 10-4, (10) 9 × 10-4, (10) 1 × 10-3. The curve (C) represents the best fit by Eq. (1) 
using a nonlinear least-squares regression method at wavelength 363 nm where the scattering is 
eliminated. 
 
TABLE 2 Partition coefficients (Kp in M-1 and LogD dimensionless) for DPPC liposomes (500 
µM, T = 60ºC pH 7.4), at the fluid phase. 
 Kp (M-1) LogD 
INH 3280 ± 729 3.7 ± 0.8 
RIF 943 ± 53 3.1 ± 0.2 
 
The Kp obtained for INH in DPPC was 3280 ± 729 and for RIF was 943 ± 53 (TABLE 
2). INH molecule contains groups that can undergo protonation (pyridine, pKa = 1.8 
and hydrazide nitrogen atoms, pKa = 3.5) and deprotonation (hydrazide group, pKa = 
10.8). According to calculations of the degree of ionization (using MarvinView® 5.4.1.1 
software from ChemAxon), at physiologic pH (7.4), INH is mainly in the neutral form, 
with a almost negligible (0.01%) of positively charged species. The predicted LogP 
A B 
C 
11 
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obtained was -0.69. As expected, the predicted LogD was the same because INH is in 
the neutral form and non-charged at the physiologic pH. Though, this value is 
contrastingly different from the experimental LogD obtained, which reinforces that 
not only the hydrophobic forces drive the drug’s partition. In fact, the ionic bonds 
and the hydrogen bounds also contribute to the partition with the membranes and 
are not or bardely accounted with the octanol/water method. In the specific case of 
INH, practically all the drug (99.99%) is the neutral form and therefore the ionic bonds 
are practically negligible [9]. Therefore, the establishment of hydrogen bonds 
between the drug and the polar head group of the phospholipids are probably 
responsible for the discrepancy of the obtained results and the predicted partition 
values. In fact, DPPC has in its composition much more groups that can serve as 
hydrogen bonds acceptors and donors in comparison with the octanol, which has 
only one hydroxyl group [60,67].  
Regarding RIF, this molecule also has groups that can undergo protonation 
(hydroxyl, pKa = 1.7) and deprotonation (piperazine nitrogen pKa = 7.9) and at 
physiologic pH, this drug is manly zwitterionic with 40% of negatively charged 
molecules [8]. The predicted LogP and LogD, obtained using the chemical software, 
were, respectively, 1.39 and 0.97. The predicted LogP is clearly higher because it does 
not account the presence of charged species at the mentioned pH. As 
abovementioned, the significantly higher value of the experimental LogD compared 
to the calculated LogD, indicates that the partition of RIF with DPPC LUVs at pH 7.4 
might be greatly driven by electrostatic interactions and hydrogen bonds with the 
polar heads of the phospholipids [60,68]. This reinforces again the idea that 
hydrophobic intermolecular forces are not the only interactions driving the drug’s 
partition, which also encodes ionic bonds due to the electrostatic interactions 
between electrically charged species and the polar head groups of the phospholipids 
[60]. 
4.2 Drug’s membrane location 
Fluorescence quenching is a sensitive method that has been widely studied as a 
source of information about biochemical systems. The quenching of a membrane 
bound fluorophore provides a measure of its accessibility to the quencher (e.g. drug). 
Therefore, if the molecular location of a probe (fluorophore) within membranes is 
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well known, quenching studies can be used to reveal the location of specific ligands 
within liposomes and biological membranes [13].  
The membrane location of INH and RIF within the lipid bilayer was assessed by 
steady-state fluorescence quenching measurements using two fluorescent probes 
(DPH and TMA-DPH). When probing the lipid membrane, the precise fluorophore 
location and depth in the bilayer are well established [69]. Several studies report that 
DPH is buried in the hydrophobic core of the membrane with a parallel alignment to 
the acyl chains, while TMA-DPH contains a DPH phenyl ring located within the 
hydrophobic acyl chains of the membrane phospholipids and a cationic group that 
anchors the probe in the polar head group region of the phospholipids. Therefore, 
TMA-DPH reports a more superficial location than DPH, nearer the phospholipid head 
groups [70-72]. 
RIF has proved to be an effective quencher of DPH and TMA-DPH, contrarily to 
INH that did not affected the fluorescence of the probes. The fluorescence quenching 
data were analyzed by the Stern-Volmer equation (Eq. (2)) [13]: 
 𝐼!𝐼 = 1 + K!"[𝑄]! (2) 
 
In this equation, I0 and I are the fluorescence intensities in the absence and 
presence of the quencher, respectively; KSV is the quenching constant, called Stern-
Volmer constant; [Q]m is the concentration of the quencher that is able to partition 
the membrane. This concentration was calculated from the total drug concentration 
([Q]T) and the drug’s partition coefficient (Kp), as described by Eq. (3) [13]: 
 [𝑄]! = 𝐾![𝑄]!𝐾!𝛼! + (1 − 𝛼!) (3) 
 
where αm is the volume fraction of membrane phase (αm = Vm/VT; Vm and VT represent, 
respectively, the volumes of the membrane and water phases). 
In FIGURE 12 is represented the Stern-Volmer plots of the probes DPH and TMA-
DPH in LUVs of DPPC by increasing concentrations of RIF (I0/I vs. [Q]m). 
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FIGURE 12 Stern-Volmer plots of the probe DPH (o) and TMA-DPH (•) in DPPC liposomes 
(500 µM, T = 60 ºC pH 7.4) by increasing concentrations (M) of the quencher RIF. 
 
The Ksv values obtained for RIF in the DPPC liposomes labeled with the probes are 
listed in TABLE 3.  
 
TABLE 3 Values of Stern-Volmer constant (KSV) at T = 60 ºC obtained for RIF in DPPC 
liposomes (500 µM, T = 60 ºC pH 7.4) labeled with DPH and TMA-DPH probes. 
 KSV (M-1) 
DPH 78 ± 16 
TMA-DPH 58 ± 13 
 
The location studies have shown that, the quenching of DPH and TMA-DPH is 
similar. These results indicate that RIF is located near both probes, being able to 
penetrate the lipid bilayer regarding the high values obtained for DPH. The molecules 
of RIF with no net charge should be inserted in the phospholipids bilayer. Moreover, 
the negatively charged molecules seem to be responsible for establishing electrostatic 
interactions with the positively charged choline present in the polar head groups of 
the phospholipids. 
In the case of INH, the drug is not able to decreases the fluorescence intensity of 
both probes even at high concentrations. These results support that INH must be 
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located at the membrane surface completely inaccessible to both probes, or has 
penetrated the bilayer so deeply, maybe reaching the aqueous vacuole of liposomes. 
4.3 Biophysical modifications of the membrane 
The effect of INH and RIF on the lipid membrane based on the change of the 
biophysical parameters of DPPC liposomes was assessed by DLS studies.  
FIGURE 13 presents, as an example, the results obtained with DPPC liposomes in 
the absence and presence of INH and RIF at pH 7.4 (FIGURE 13A) (FIGURE 13B), 
respectively. 
 
FIGURE 13 Count rate plots in absence (n) and presence () of INH (30 µM) (A) and RIF (30 
µM) (B) in DPPC liposomes at pH = 7.4 as a function of temperature. 
 
Using the count rate to determinate the Tm of the lipid vesicles, this technique is 
reliable, simple and reproducible. The mean count rate (average number of photons 
detected per second) versus temperature were collected and fitted using the Eq. (4) 
[60,62]:  
 𝑟! = 𝑟!! + 𝑝!𝑇 + 𝑟!! − 𝑟!! + 𝑝!𝑇 − 𝑝!𝑇1 + 10!(! !!! !!)  (4) 
 
In this equation, rs is the average count rate, T is the temperature (ºC), p1 and p2 
correspond to the slopes of the straight lines at the beginning and at the end of the 
plot, rs1 and rs2 are the respective count rate intercepting values at the y axis. From the 
fitted data, it was possible to determine the cooperativity (B) and the midpoint of the 
A B 
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phase transition, which corresponds to the temperature of the gel-to-fluid transition 
of DPPC (Tm). 
The values of cooperativity (B) and main phase transition temperature (Tm) 
obtained for DPPC in the presence of INH or RIF are listed in TABLE 4.  
 
TABLE 4 Values of main phase transition temperature (Tm) and cooperativity (B) obtained for 
DPPC liposomes (500 µM, T = 60.0 °C pH 7.4) in the absence and in the presence of INH or RIF (30 
µM). 
 Tm (ºC) Cooperativity (B) 
DPPC 40.2 ± 0.6 901 ± 90 
DPPC + RIF 40.8 ± 0.1 1039 ± 57 
DPPC + INH 41.0 ± 0.3 1585 ± 69 
 
 The Tm and cooperativity values obtained for DPPC liposomes are consistent with 
previous reported studies [59,61,72]. 
The incorporation of INH and RIF did not affect Tm of DPPC, however in case of INH 
has affected significantly the lipid alkyl chain cooperativity (i.e., the number of chains 
that change simultaneously). Thus, INH increases the cooperativity of the phase 
transition in DPPC, which endorses that this anti-TB drug interacts with the lipid 
bilayer of the DPPC liposomes. Moreover, alterations in the biophysical parameters of 
the lipids give an indication about the location of the drugs within the lipid bilayers 
[72]. In fact, lipid bilayers are characterized by a fluidity gradient at both gel and fluid 
phases, i.e., the deeper region of the hydrocarbon chains near the center of the 
bilayer is more “fluid” and disordered (C10-C16) than the outer region of the chains 
near the phospholipids polar group (C1-C9) [68,73]. Therefore, biophysical parameters 
of the membranes, such as the cooperativity, are greatly influenced by the interaction 
of the drug in the C1-C9 ordered regions of the acyl chains. So, if a drug induces 
changes in the cooperativity and Tm is more likely to be located in the chain region 
near to the polar head groups (C1-C9). Contrastingly, if the drug has little or no effect 
in the biophysical parameters is more likely to be located in the disordered bilayer 
core (C10-C16) [72]. 
Therefore, the analysis of the changes, induced by the drugs, in the biophysical 
parameters of the membrane model permits to draw conclusions about the drugs 
location within the lipid bilayer. These results reinforce the location of INH closer to 
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the polar head groups of phospholipids, since this drug changes the cooperativity of 
the phase transition. On the other hand, RIF a bulkier molecule does not change the 
biophysical parameters of the lipids, possible due to a deeper penetration with the 
lipid bilayer in comparison with the INH. 
These findings are in agreement with the abovementioned results of partition 
coefficient and location studies. Indeed, the interaction of INH with the membrane is 
essentially driven by the interactions of the drug with the polar head groups of the 
phospholipids via hydrogen bonds and hydrophobic forces, whereas the partition of 
RIF involves ionic bonds with the choline of the phospholipids head groups, possible 
hydrogen bonds and hydrophobic forces, specially in the case of the zwitterionic 
species. 
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CHAPTER 5  
THE CONCLUSIONS 
In any kind of disease, and specially in the case of TB, one of the main goals to 
defeat it is to find more effective and safer drugs [29]. 
After drug’s administration, these bioactive compounds interact with many 
biomembranes along the body. Therefore, the study of the drug-membrane 
interaction, at the physiological or pathological conditions, constitutes a preliminary 
step to the biological (and toxic) study, as it can affect the rate of penetration of the 
drug in order to reach its pharmacological target, an ultimately to understand their 
therapeutic effects [74]. 
To understand how INH and RIF penetrate into the membranes, what are the 
membrane’s biophysical consequences induced by the drugs and where their 
preferentially locate in the lipid bilayer, which in turn can be related with their 
mechanism of entrance into the cellular compartments, bioavailability and toxic 
effects, some biophysical techniques were performed, such as Kp, fluorescence 
quenching and DLS. 
The overall results reveal that the partition of both drugs is high,  having both 
drugs desirable characteristics in terms of the logD for an anti-TB drug. These 
findings also highlight how limited and unsatisfactory are the conventional models 
for predicting Kp, based on the octanol-water partitioning, mainly because they only 
account for hydrophobic interactions [66]. In fact, drugs can interact with membranes 
trough hydrogen bonds, which seem to be the main force responsible for the INH 
partitioning. The partition of the negatively charged molecules of RIF with 
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membranes occurs due to the ionic bonds and probably hydrogen bonds with the 
polar head groups of the phospholipids. The zwitterionic species, which are more 
hydrophobic probably, interact more deeply with the lipid bilayers. INH did not 
influenced the fluorescence of DPH and TMA-DPH probes, indicating that it must be 
located at the membrane surface completely inaccessible to both probes or has 
penetrated the bilayer so deeply, maybe reaching the aqueous vacuole of liposomes.  
With these studies it is possible to establish important correlations with drug’s 
therapeutic and toxic effects. In case of INH, some of the side effects include mental 
abnormalities, meaning that this drug passes the hematoencephalic barrier, being 
this probably related with the high lipophilicty described in this work for this drug. 
On the other hand, it is well known that DPPC lines the luminal aspects of the mucus 
gel layer providing the stomach with a protective layer of surface-active 
phospholipids, and therefore the epigastric distress caused by INH may be related 
with its preferential location at the head groups of the phospholipids, promoting a 
disruption of this protective layer [72]. Regarding to RIF, it is possible to correlate the 
discoloration of the skin and body fluids with RIF’s high partitioning and great 
distribution trough the body. In a similar way described for INH the gastrointestinal 
disturbances may also be related with its location close to the phospholipid head 
groups and consequently impairment of the protective gastric layer. 
Analysis of the biophysical interactions between drugs and biomembranes are 
becoming a settled part of the design, discovery, and characterization of new drugs 
candidates. Many different analytical techniques have been applied or developed on 
purpose to perform these kinds of studies. Using artificial membranes, as simplified 
models for cell membranes has given a strong input to the understanding of the 
complex set of interactions that a biomolecule can develop toward biological 
membranes. 
In conclusion, the findings of this work represent a contribution to the medicinal 
chemistry field and permit to understand the interactions of INH an RIF with 
membranes, which are putatively related to the mechanism of action of these anti-TB 
drugs and therefore contribute to the discovery of new anti-TB drugs that effectively 
fight the TB. 
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FUTURE PERSPECTIVES 
For future work, membrane models closer to biologic membranes could be used, 
incorporating cholesterol, glycolipids and proteins. Studies with mycolic acids that 
mimicks the MTb wall could also help to better understand the interactions of these 
drugs with the bacteria membrane. 
Simulating different environment conditions, similar to those found in the 
infected macrophages by MTb, such as pH’s of 5.0 and 6.2 could also help to 
understand the biophysical interactions and mechanism of action of these drugs.  
Another techniques could also be used, such as differential scanning calorimetry 
(DSC) and steady-state anisotropy to study the influence of INH and RIF in the 
membrane biophysical properties. In addition, lifetime measurements could also be 
performed in order to understand the quenching mechanism of RIF. 
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